PowerShares Intl Div Achiev ETF

Most Recent

  • uploads///Wholesale Segment Gross Margin
    Earnings Report

    What Benefited Agrium’s Wholesale Gross Margins in 1Q16?

    Agrium’s Wholesale segment’s gross margins declined from 27% in 1Q15 to 24% in 1Q16. This was primarily driven by a decline in gross margins in the Nitrogen and Phosphates segments.

    By Adam Jones
  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Agriums Gross Profit and Margins Expectations
    Earnings Report

    Will Agrium’s 1Q16 Gross Margins Weaken?

    Agrium (AGU) earns most of its revenues from its retail sales channel. However, when it comes to gross margins, the wholesale channel is more profitable.

    By Adam Jones
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Focusing on These Strategic Areas in 2016

    With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Novartis’s 1Q16 Earnings Got a Neutral Response from Investors

    Novartis (NVS) released its 1Q16 earnings on April 21, 2016. It reported top-line growth of 1% at constant exchange rates for 1Q16—compared to 1Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline Increases Top Line in 2Q16

    GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Share of the US Generics Market Could Boost Its Stock

    Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

    By Margaret Patrick
  • uploads///Cost to drill a shale gas well in the Sichuan Basin
    Macroeconomic Analysis

    Joint Ventures in US Shale Plays Are Helping Chinese Companies Bring Down Well Drilling Costs

    To get expertise in shale gas exploration, China has invested more than 20% of the total investments in US shale gas exploration.

    By Manu Milan
  • uploads///Chart
    Company & Industry Overviews

    How Merial Contributes to Sanofi’s Growth

    Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Innovative Medicines Segment

    Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: Innovative Medicines Segment

    The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

    By Mike Benson
  • uploads///human geentics therapies
    Earnings Report

    What to Expect from Shire’s Genetic Disease Franchise

    Wall Street analysts expect Elaprase to earn $145.6 million in 2Q16 and $140.5 million in 3Q16.

    By Jillian Dabney
  • uploads///Chart
    Miscellaneous

    Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines

    Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 2Q16 Earnings: What’s Expected?

    Analysts have given Novartis’s stock a 12-month target price of $92.50 per share, as compared to the last closing price of $81.61 per share on July 15.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Shire: Why Analysts Expect Revenue Growth in Q3 2018

    Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Shire’s Valuation on September 19

    Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.

    By Mike Benson
  • uploads///pills _
    Company & Industry Overviews

    Novartis’s Valuation in August

    Novartis (NVS), a leading pharmaceutical company, reported EPS of $1.29 on revenues of $13.2 billion in Q2 2018, a 5% growth year-over-year.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Business in 4Q17

    Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Performance of Sanofi’s Business Segments in 4Q17

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

    By Mike Benson
  • uploads///debt maturities
    Company & Industry Overviews

    How Wall Street Reacted to Berkshire Hathaway Investment in Teva

    Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

    By Sarah Collins
  • uploads///bioverativ_businessprofile
    Company & Industry Overviews

    Exploring Bioverativ’s Business Profile and Market Presence

    Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.

    By Sarah Collins
  • uploads///rev eps pba
    Miscellaneous

    PBA’s Dividends: Key Drivers

    Pembina Pipeline Corporation (PBA) offers transportation and midstream services in North America. Its revenue fell 8% in 2016 before gaining 22% in 9M17.

    By Amanda Lawrence
  • uploads///rev eps trp
    Miscellaneous

    TRP’s Dividends: Key Drivers

    TransCanada Corporation (TRP) is an energy infrastructure company in North America. Its revenue grew 11% in both 2016 and 9M17.

    By Amanda Lawrence
  • uploads///rev eps enb
    Miscellaneous

    What Could Continue to Drive ENB’s Dividends

    Enbridge (ENB) is involved in energy transportation in the United States and Canada. Revenue grew 2% in 2016, compared to 25% in 9M17.

    By Amanda Lawrence
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Sandoz Business

    Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.

    By Mike Benson
  • uploads///Ablynx
    Company & Industry Overviews

    How Sanofi Can Benefit from Ablynx Acquisition

    On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.

    By Daniel Collins
  • uploads///Sandoz
    Company & Industry Overviews

    How Is Novartis’s Subsidiary Sandoz Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Sandoz generated revenues of $2.4 billion, $2.5 billion, and $2.6 billion, respectively.

    By Daniel Collins
  • uploads///Chart  Inno Medicines
    Earnings Report

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17

    Sanofi’s (SNY) general medicines and emerging markets sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.

    By Mike Benson
  • uploads///CNS
    Company & Industry Overviews

    How Did Teva’s CNS Portfolio Perform in 3Q17?

    Teva CNS drugs generated 3Q17 revenues of $1.1 billion, which was ~12% lower YoY (year-over-year) and ~1% lower QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///REV EPS XEC
    Energy & Utilities

    How Did Cimarex Energy’s Dividend Cut Affect Its Dividend Yield?

    Cimarex Energy’s (XEC) revenues fell 40.0% and 13.0% in 2015 and 2016, respectively.

    By Amanda Lawrence
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s 3Q17 Revenue Growth

    Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.

    By Mike Benson
  • uploads///Part  MEOH
    Company & Industry Overviews

    Behind Methanex’s Long-Term Agreement with Painted Pony Energy

    On November 8, Methanex announced that it entered into a 14-year agreement with Painted Pony Energy for natural gas supplies to its Alberta methanol plant.

    By Peter Neil
  • uploads///DIV VMC
    Basic Materials

    What’s Led to Vulcan Materials’ Upward Dividend Yield Curve

    Vulcan’s dividend yield Vulcan Materials’ (VMC) 100% dividend-per-share growth in 2016 has been followed by 25% growth in 2017. Its dividend yield curve has sloped upward due to growth in its dividend per share and a sharp drop in its stock price growth. Its stock price has risen 1% YTD (year-to-date), compared with 32% in 2016. The company, like the overall […]

    By Amanda Lawrence
  • uploads///Chart  Rev
    Earnings Report

    Why Sanofi’s Revenues Could Fall in 3Q17

    Analysts estimate Sanofi’s (SNY) revenues will fall 2.2% to 9.44 billion euros during 3Q17.

    By Mike Benson
  • uploads///REV EPS CAE
    Miscellaneous

    What Affected CAE’s Dividend Yield?

    CAE (CAE) is an international frontrunner in the delivery of training for the civil aviation, defense and security, and healthcare markets.

    By Amanda Lawrence
  • uploads///Chart  SNY
    Miscellaneous

    Sanofi Stock: Performance in 3Q17

    Sanofi stock has risen ~3.9% in 3Q17. It has risen 22.5% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///respiratory
    Company & Industry Overviews

    How Are Novartis’s Respiratory Drugs Positioned after 1H17?

    In 1H17, Novartis’s (NVS) COPD (chronic obstructive pulmonary disorder) portfolio reported revenues of around $318 million.

    By Daniel Collins
  • uploads///Azilect
    Company & Industry Overviews

    How TEVA’s CNS Drugs Performed in 1H17

    In 1H17, Teva Pharmaceutical’s (TEVA) CNS (central nervous system) business generated revenues of ~$2.3 billion, or ~16% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Generics revenues
    Company & Industry Overviews

    How TEVA’s Generic Medicines Franchise Is Positioned after 1H17

    In 1H17, Teva Pharmaceutical’s (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year).

    By Daniel Collins
  • uploads///OKE PRICE
    Energy & Utilities

    How ONEOK Has Managed Its Impressive Dividend Yield

    How ONEOK has maintained a 4% yield ONEOK (OKE), the general partner and 41% owner of ONEOK Partners, owns one of the country’s premier natural gas liquid systems. The company’s revenue grew 15% in 2016 after falling 36% in 2015. The growth was driven by its Natural Gas Gathering and Processing, Natural Gas Liquids, and […]

    By Amanda Lawrence
  • uploads///Chart  Inno
    Company & Industry Overviews

    What Happened to Novartis’s Innovative Medicines Business in 2Q17?

    Novartis’s Innovative Medicines segment contributed over 67% of NVS’s total revenues at nearly $8.3 billion for the quarter.

    By Mike Benson
  • uploads///DY SWK
    Industrials

    Dividend Yield of Stanley Black & Decker

    Stanley Black & Decker’s (SWK) PE ratio of 21.1x is pitted against a sector average of 29.3x. The dividend yield of 1.8% is pitted against a sector average of 1.6%.

    By Amanda Lawrence
  • uploads///Chart  Vaccines
    Company & Industry Overviews

    A Look at Sanofi Pasteur’s Performance in 2Q17

    Sanofi Pasteur Sanofi Pasteur, Sanofi’s (SNY) human vaccine business, reported 26.2% revenue growth at constant exchange rates to 1.0 billion euros in 2Q17. Sanofi Pasteur reported growth across all product franchises during the quarter. Sanofi Pasteur includes polio/pertussis/Hib (haemophilus influenzae type b) vaccines, adult booster vaccines, meningitis vaccines, influenza vaccines, travel and other endemic vaccines, […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    North America: Fresenius Medical Care’s Major Target Market in 2017

    In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.

    By Margaret Patrick
  • uploads///Chart  Genzyme
    Company & Industry Overviews

    Sanofi Genzyme Continues Driving Revenue Growth in 2Q17

    Sanofi Genzyme In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product revenue from the multiple sclerosis, rare disease, oncology, and immunology franchises, reported a sales increase of ~14.6% to 1.7 billion euros. This rise was […]

    By Mike Benson
  • uploads///KMBVS
    Consumer

    Kimberly-Clark’s Dividend Growth

    Kimberly-Clark’s (KMB) 2016 net sales fell 2.0% due to declines in every segment.

    By Amanda Lawrence
  • uploads///Chart  Sandoz
    Earnings Report

    Novartis in 2Q17: Performance of Sandoz

    Sandoz contributed ~20.0% of total revenues at $2.45 billion in 2Q17, a 5.0% fall compared to $2.58 billion in 2Q16.

    By Mike Benson
  • uploads///Chart  Rev n EPS
    Earnings Report

    Analysts Expect Novartis’s Revenues to Fall in 2Q17

    Analysts expect Novartis’s (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    Inside Novartis’s Segment-Wise Performance in 1Q17

    Novartis is largely exposed to currency risk, as ~50% of its total revenues are reported from international markets.

    By Mike Benson
  • uploads///Chart  ERx
    Company & Industry Overviews

    Performance of Sanofi’s Established Prescription Products in 1Q17

    Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.

    By Mike Benson
  • uploads///Chart  Vaccines
    Earnings Report

    How GlaxoSmithKline’s Vaccines Business Performed in 1Q17

    GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS).

    By Mike Benson
  • uploads///Chart  Segm Rev
    Earnings Report

    How GlaxoSmithKline’s Business Segments Performed in 1Q17

    The company reported operational growth of 5% in its revenues to 7.4 billion pounds for 1Q17.

    By Mike Benson
  • uploads///Chart  Inno
    Earnings Report

    Novartis’s 1Q17 Earnings: Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment contributed ~66.6% to overall 1Q17 revenue, or $7.7 billion.

    By Mike Benson
  • uploads///Chart  Vaccines
    Earnings Report

    GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business

    The Novartis acquisition has improved sales for GSK’s Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.

    By Mike Benson
  • uploads///chart_ __ _ratings
    Miscellaneous

    Analyst Ratings and Recommendations for Novartis

    As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a “buy.”

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Analyst Estimates for Novartis’s 1Q17 Earnings

    Novartis is set to release its 1Q17 earnings on April 25, 2017. Analysts estimate its 1Q17 EPS at $1.12 with revenues of ~$11.7 billion.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Novartis Expects to Restore Alcon’s Profitability in the Future

    Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Sanofi Genzyme Continued Growth in 2016

    Sanofi’s (SNY) 2016 revenues were mainly driven by Sanofi Genzyme and Sanofi Pasteur.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Reduced Co-pays May Boost Demand for Entresto

    Compared to 43% at the end of 2015, Novartis’s (NVS) Entresto managed to attain a preferred formulary position in 66% of commercial plans in the US at the end of 2016.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Performance of GlaxoSmithKline’s Vaccines Business in 2016

    GSK’s Vaccines business reported growth of 14% to ~4.6 billion pounds in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Pharmaceuticals Segment Performance

    Overall, the Pharmaceutical segment’s contribution to GSK’s total revenues was 57.7% in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sandoz: Novartis’s Generics Business in 2016

    Sandoz, the generics arm of Novartis (NVS), is the number two generic medicines provider worldwide, and it’s number one in differentiated generics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Segment in 2016

    Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Happened to Sanofi’s Valuation after 4Q16?

    On February 16, 2017, Sanofi was trading at a forward PE multiple of ~13.9x, as compared to the industry average of 15.7x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    This Keeps Driving Sanofi’s Growth

    Sanofi’s (SNY) 4Q16 revenues were mainly driven by Genzyme and Sanofi Pasteur.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16

    GSK’s Vaccines segment reported a rise of 18.0% to 1.1 billion pounds in 4Q16. The Novartis acquisition has improved sales for the segment.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    4Q16 Performance of GlaxoSmithKline’s Business Segments

    Revenues for GSK’s Pharmaceuticals segment saw a shift in product performance, falling due to lower sales of its key products Seretide and Advair.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Segment in 4Q16

    The overall contribution from NVS’s Innovative Medicines segment was ~67%, reaching $8.3 billion in 4Q16.

    By Mike Benson
  • uploads///Nitrogen Segments Average Selling Prices
    Earnings Report

    PotashCorp in 4Q16: Nitrogen Prices Added Salt to the Wound

    In 4Q16, the overall average nitrogen selling price fell 37.0% to $182 per ton, from $288 per ton in 4Q15.

    By Adam Jones
  • uploads///Chart
    Company & Industry Overviews

    How Did Novartis’s Generics Business Perform in 3Q16?

    Sandoz reported a decline of 1% in 3Q16 revenues at constant exchange rates.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment fell substantially in 2015 due to its divestment of its oncology business to Novartis (NVS) in March 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Sandoz Performed for Novartis in 3Q16

    Sandoz, the generics arm of Novartis (NVS), is the number-two generic medicines provider worldwide. It’s number one in differentiated generics.

    By Mike Benson
  • uploads///tresiba
    Earnings Report

    How Tresiba Helps Novo Achieve Its Growth Targets

    During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner.

    By Jillian Dabney
  • uploads///victoza
    Earnings Report

    Victoza Dominates Global GLP-1 Class

    Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients.

    By Jillian Dabney
  • uploads///global insulin segments
    Earnings Report

    Reading Novo’s Insulin Portfolio to Find Clues about Its Growth

    Novo Nordisk’s (NVO) diabetes and obesity care portfolio consists of modern insulin, Victoza, human insulin, new generation insulin, and other diabetes and obesity care products.

    By Jillian Dabney
  • uploads///US sales
    Earnings Report

    US Still the Largest Market for Novo Nordisk

    During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner.

    By Jillian Dabney
  • uploads///Nitrogen Segments Average Selling Prices
    Earnings Report

    Why Did PotashCorp’s Nitrogen Prices Fall in 3Q16?

    Nitrogen selling prices PotashCorp (POT) sells nitrogen fertilizers such as ammonia, urea, and nitrogen solutions. It competes with other natural gas–based nitrogen producers such as CF Industries (CF) and Terra Nitrogen (TNH), which primarily produce and sell nitrogen fertilizers. Agrium (AGU), which is a part of the PowerShares International Dividend Achievers ETF (PID), produces nitrogen fertilizers […]

    By Adam Jones
  • uploads///anr
    Earnings Report

    How Much Is the Return Opportunity for Novo Nordisk in 3Q16?

    A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Will Alcon Recover Its Growth?

    Alcon, Novartis’s (NVS) eye care segment, researches, develops, manufactures, and markets eye care products in over 180 countries worldwide.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Expects to Witness Strong Growth from New Product Launches

    In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Expected to See Strong Growth in Insulin Segment

    Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Winning? We Review How Teva Dominates Generic Drug Space

    Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.

    By Margaret Patrick
  • uploads///vaccine
    Company & Industry Overviews

    Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price

    Sanofi’s Vaccine segment generated 1.4 billion euros, or about $1.6 billion, during the first half of 2016.

    By Jillian Dabney
  • uploads///lantus
    Company & Industry Overviews

    Will Sanofi See More Growth from Its Blockbuster Insulin Drug?

    Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    GSK Optimistic about Future of Its Consumer Healthcare Segment

    With improvements in the supply chain and successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline Giving a Shot to Its Vaccines Business

    GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired Novartis’s (NVS) meningitis and other vaccines business.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition

    GlaxoSmithKline’s (GSK) HIV medicines business is managed by ViiV Healthcare, a global specialist company in HIV medicines.

    By Mike Benson
  • uploads///Sanofi assset swap
    Company & Industry Overviews

    Analyzing Sanofi’s Asset Swap Deal with Boehringer Ingelheim

    Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical: A Successful Bond Financing Program in 2016

    To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?

    Sanofi’s Consumer Healthcare segment includes Allegra, Doliprane, Nasacort, and other products. It reported a 4.3% decline in revenues to 800 million euros.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16

    Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Genzyme Continued to Boost Growth for Sanofi in 2Q16

    After Sanofi’s reorganization, Genzyme now includes products for multiple sclerosis, rare diseases, and oncology. Genzyme’s sales increased ~19.5% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Sanofi’s Valuation Changes

    With rising sales of in its Genzyme, Animal Health, and Vaccines segments, Sanofi has reported a growing top line over the past few quarters.

    By Mike Benson
  • uploads///sales geo graphywise
    Earnings Report

    How Did Novo Nordisk Perform across Geographies in 1H16?

    As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market.

    By Jillian Dabney
  • uploads///pipeline
    Earnings Report

    An Update on Shire’s Upcoming Milestones

    Shire anticipates receiving European Union approval for Natpara for the indication of hyperparathyroidism in 4Q16.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.